Bacterial Endocarditis and Septic Arthritis in a Patient With Severe Hemophilia A

Titapiwatanakun, Ruetima; Pruthi, Rajiv K.; Schmidt, Kirstin; Slaby, J. A.; Rodriguez, Vilmarie

doi:10.1097/mph.0b013e31818c91b8

Cited by 7 publications

(1 citation statement)

References 13 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three published case reports have described invasive Staph. aureus infections in haemophilia patients which were also presumed to be CVAD‐related with haematogenous dissemination [33,34,35]. In one case, the infection led to a fatality.…”

Section: Discussionmentioning

confidence: 99%

Monthly recombinant tissue plasminogen activator administration to implantable central venous access devices decreases infections in children with haemophilia

Jeng¹,

O’Brien²,

Wong³

et al. 2009

Haemophilia

View full text Add to dashboard Cite

Central venous access devices (CVAD) have been effectively used in the care of haemophilia patients. This is particularly true in children, who often have difficult venous access. CVAD complications (infection and thrombosis), risk factors, and complication rates, have been well-documented. However, effective interventions which decrease complication rates have not been identified. In this study, we review our experience with the use of monthly recombinant tissue plasminogen activator (rtPA) administration in haemophilia patients with fully implanted CVADs. Data on 19 haemophilia patients with 24 CVADs were available for analysis, with a total of 24 520 CVAD days. An infection rate of 0.04 infections per 1000 CVAD days and a thrombosis rate of 0.04 thrombi per 1000 CVAD days was observed. The observed infectious complication rate is at least one logarithm lower than many published CVAD infection rates in haemophilia patients who have not received rtPA administration. No bleeding complications were noted. Monthly rtPA is safe and appears to be effective in decreasing CVAD infection rates. Larger, randomized controlled studies are indicated to validate this finding.

show abstract

Section: Discussionmentioning

confidence: 99%

Monthly recombinant tissue plasminogen activator administration to implantable central venous access devices decreases infections in children with haemophilia

Jeng¹,

O’Brien²,

Wong³

et al. 2009

Haemophilia

View full text Add to dashboard Cite

show abstract

Septische Arthritis als Manifestation einer floriden Endokarditis

et al. 2012

View full text Add to dashboard Cite

Septic arthritis due to endocarditis is a rare and life-threatening disease. Endocarditis occurs with an incidence of 30 patients per 1 million citizens/year. Staphylococcus aureus is one of the most common causative pathogens. Methicillin-resistant Staphylococcus aureus (MRSA) can lead to a severe outcome with a high mortality rate, and embolic complications of the kidney, brain, and spleen are seen in one third of all cases. The diagnosis and treatment of endocarditis is a challenge for all health care providers. We report about a patient who was admitted to our hospital with generalized sepsis of unknown origin.

show abstract

Septic Arthritis in Pediatric Hemophilia A: A Case Report and Review of Literature

Das

Ghosh

Rajbangshi

et al. 2021

JOIO

View full text Add to dashboard Cite

Bacterial Endocarditis and Septic Arthritis in a Patient With Severe Hemophilia A

Cited by 7 publications

References 13 publications

Monthly recombinant tissue plasminogen activator administration to implantable central venous access devices decreases infections in children with haemophilia

Monthly recombinant tissue plasminogen activator administration to implantable central venous access devices decreases infections in children with haemophilia

Septische Arthritis als Manifestation einer floriden Endokarditis

Septic Arthritis in Pediatric Hemophilia A: A Case Report and Review of Literature

Contact Info

Product

Resources

About